A clinical stage biopharmaceutical company that is focused on developing and manufacturing recombinant therapeutic proteins that are produced through its proprietary plant cell system.


Updates from The Motley Fool

Latest updates on Protalix BioTherapeutics from Fool.com.
4 Longshot Stocks to Invest In

These companies are stuffed full of potential, but may be lacking in the results department. They...

This Week in Biotech

A look back at the biggest stories this week in biotech and what they mean for investors.

The Big Bet on Protalix

Will the FDA approve Protalix's taligucerase on its second attempt?



Stock Performance

View Interactive PLX Charts
Sponsored by

Key Data Points

Primary metrics and data points about Protalix BioTherapeutics.
Current Price: $1.00
Prev Close: $1.00
Open: $1.00
Bid: $1.00
Ask: $1.02
Day's Range: $0.99 - $1.01
52wk Range: $0.26 - $1.51
Volume: 849,077
Avg Vol 3,241,128
Market Cap: $124M
P/E (ttm): -3.43
EPS (ttm): ($0.29)
Div & Yield: $0.00 (0.0%)

Company Rating

What our community thinks about Protalix BioTherapeutics.
CAPS Rating 2 out of 5
 
162 Outperform
72 Underperform
CAPS All Stars
 
22 Outperform
20 Underperform

How do you think Protalix BioTherapeutics will perform against the market?



You pick for Protalix BioTherapeutics is winning

Score: +97.74
Call: Outperform
Time Frame: Five Plus Years
Start Price: $18.24
Start Date: 3/29/2007
Gain/Loss: +$152.4%
S&P Gain/Loss: +$54.7%

Powered by Motley Fool CAPS


CEO Rating

The single most important factor in a company's success is the team that's leading the company.

David Aviezer, CEO

0% Approve

Based on 0 Ratings

Powered by Glassdoor

Business Summary

Industry, sector and description for Protalix BioTherapeutics.

A clinical stage biopharmaceutical company that is focused on developing and manufacturing recombinant therapeutic proteins that are produced through its proprietary plant cell system.

  • Exchange: NYSEMKT
  • Sector: Healthcare
  • Industry: Drug Makers